Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.40 |
| ▸ | APP | P05067 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23345270 | 1.00 | ATM (0.44) | ATMHTTSMN1; SMN2HCAR2APP | |
| SCHEMBL29918598 | 0.89 | CA12 (0.38) | HCAR2MAPTRAB9A | |
| SCHEMBL29059996 | 0.82 | KMT2A (0.37) | SMN1; SMN2HCAR2APPMAPTHPGD | |
| SCHEMBL30556387 | 0.82 | KMT2A (0.37) | SMN1; SMN2HCAR2APPMAPTHPGD | |
| SCHEMBL30579685 | 0.81 | ATM (0.44) | ATMHTTSMN1; SMN2HCAR2APP | |
| SCHEMBL30122313 | 0.81 | CA12 (0.36) | HCAR2MAPTRAB9A | |
| SCHEMBL23326490 | 0.76 | L3MBTL1 (0.42) | SMN1; SMN2HCAR2 | |
| SCHEMBL25743158 | 0.76 | CA12 (0.45) | HCAR2MAPTRAB9A | |
| SCHEMBL29154691 | 0.71 | CNKSR1 (0.43) | HTTHCAR2MAPTRAB9AHPGD | |
| SCHEMBL30739070 | 0.71 | CNKSR1 (0.43) | HTTHCAR2MAPTRAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4620531-A2 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12258366-B2 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-11-16 | — | — | US | disclosed |
| EP-4055017-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | ATM 4089/4885HTT 3916/4885SMN1; SMN2 432/4885 |
| US-12258366-B2 | Bicyclic heteroaryl compounds and uses thereof | SOST, SOS1, SOS2 | ATM 4089/4885HTT 3916/4885SMN1; SMN2 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.